- Home
- HCI vs AUPH Comparison
HCI vs AUPH Comparison
Compare HCI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- AUPH
- Stock Information
- Founded
- HCI 2006
- AUPH 1993
- Country
- HCI United States
- AUPH Canada
- Employees
- HCI N/A
- AUPH N/A
- Industry
- HCI Property-Casualty Insurers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- AUPH Health Care
- Exchange
- HCI Nasdaq
- AUPH Nasdaq
- Market Cap
- HCI 1.7B
- AUPH 1.1B
- IPO Year
- HCI N/A
- AUPH 1999
- Fundamental
- Price
- HCI $151.98
- AUPH $8.77
- Analyst Decision
- HCI Strong Buy
- AUPH Strong Buy
- Analyst Count
- HCI 4
- AUPH 2
- Target Price
- HCI $181.25
- AUPH $11.50
- AVG Volume (30 Days)
- HCI 162.5K
- AUPH 1.4M
- Earning Date
- HCI 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- HCI 1.05%
- AUPH N/A
- EPS Growth
- HCI 4.05
- AUPH N/A
- EPS
- HCI 10.46
- AUPH 0.27
- Revenue
- HCI $759,870,000.00
- AUPH $247,295,000.00
- Revenue This Year
- HCI $19.25
- AUPH $12.15
- Revenue Next Year
- HCI $4.08
- AUPH $18.31
- P/E Ratio
- HCI $14.61
- AUPH $31.76
- Revenue Growth
- HCI 20.95
- AUPH 29.20
- 52 Week Low
- HCI $83.65
- AUPH $5.20
- 52 Week High
- HCI $176.40
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- HCI 41.67
- AUPH 66.00
- Support Level
- HCI $145.30
- AUPH $7.71
- Resistance Level
- HCI $150.86
- AUPH $8.29
- Average True Range (ATR)
- HCI 4.84
- AUPH 0.25
- MACD
- HCI -1.44
- AUPH 0.03
- Stochastic Oscillator
- HCI 20.75
- AUPH 84.40
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.